DK0536282T3 - Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker - Google Patents

Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker

Info

Publication number
DK0536282T3
DK0536282T3 DK91912759.7T DK91912759T DK0536282T3 DK 0536282 T3 DK0536282 T3 DK 0536282T3 DK 91912759 T DK91912759 T DK 91912759T DK 0536282 T3 DK0536282 T3 DK 0536282T3
Authority
DK
Denmark
Prior art keywords
humans
treating prostate
prostate adenocarcinoma
alpha
reductase inhibiting
Prior art date
Application number
DK91912759.7T
Other languages
English (en)
Inventor
Keith Johnson Randall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24173248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0536282(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK0536282T3 publication Critical patent/DK0536282T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91912759.7T 1990-06-27 1991-06-21 Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker DK0536282T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/544,709 US5300294A (en) 1990-06-27 1990-06-27 Method of treating prostatic adenocarcinoma

Publications (1)

Publication Number Publication Date
DK0536282T3 true DK0536282T3 (da) 1997-10-27

Family

ID=24173248

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91912759.7T DK0536282T3 (da) 1990-06-27 1991-06-21 Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker

Country Status (15)

Country Link
US (2) US5300294A (da)
EP (1) EP0536282B1 (da)
JP (5) JP2702280B2 (da)
KR (1) KR100209825B1 (da)
AT (1) ATE151635T1 (da)
AU (1) AU650033B2 (da)
CA (1) CA2084775C (da)
DE (1) DE69125714T2 (da)
DK (1) DK0536282T3 (da)
ES (1) ES2100952T3 (da)
GR (1) GR3024064T3 (da)
HK (1) HK1006412A1 (da)
IE (1) IE81134B1 (da)
WO (1) WO1992000010A1 (da)
ZA (1) ZA914919B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5239075A (en) * 1991-08-21 1993-08-24 Eli Lilly And Company Process for the preparation of benzo (f) quinolinones
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
JPH07508033A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ５α−レダクターゼ阻害剤としての３−オキソ−４−アザステロイドの新規１７−エステル，アミド及びケトン誘導体
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
US5882681A (en) * 1993-09-03 1999-03-16 Smithkline Beecham Corporation Stabilized tablet formulation
US5578724A (en) * 1994-09-20 1996-11-26 Eli Lilly And Company Process for preparation of benzo[f]quinolinones
US5763490A (en) * 1994-09-20 1998-06-09 University Of South Carolina Treating prostate cancer with tartrate ions
US5629007A (en) * 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) * 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
JPH09172979A (ja) * 1995-12-27 1997-07-08 Ajinomoto Co Inc 新規リン酸アミノ酸複合塩及び制酸剤を含有する反すう動物用飼料添加組成物
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
GB9717444D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US6365181B1 (en) 2000-04-20 2002-04-02 Gattefosse Corporation Thixatropic gelatin carrier composition
CN1980668A (zh) * 2004-01-28 2007-06-13 安德鲁科技有限公司 通过作用于类固醇依赖性基因激活路径不同步骤中抑制剂的组合而增强抗雄激素活性及用途
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
DK2104659T3 (en) 2007-01-08 2015-11-02 Allianz Pharmascience Ltd Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
CA2694953C (en) 2007-07-31 2015-12-01 Androscience Corporation Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
EP4066841A1 (en) 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
JPS63203625A (ja) * 1987-02-19 1988-08-23 Kao Corp ５α−リダクタ−ゼ阻害剤
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US5041433A (en) * 1987-04-29 1991-08-20 Smithkline Beecham Corporation 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
AU5851690A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Method of treatment of androgen-related diseases
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma

Also Published As

Publication number Publication date
JP2702280B2 (ja) 1998-01-21
IE81134B1 (en) 2000-03-22
US5496556A (en) 1996-03-05
WO1992000010A1 (en) 1992-01-09
AU650033B2 (en) 1994-06-09
JPH1081625A (ja) 1998-03-31
JP2000309536A (ja) 2000-11-07
JPH05508155A (ja) 1993-11-18
ZA914919B (en) 1992-07-29
CA2084775C (en) 2003-04-15
US5300294A (en) 1994-04-05
DE69125714D1 (de) 1997-05-22
EP0536282A1 (en) 1993-04-14
KR930701175A (ko) 1993-06-11
KR100209825B1 (ko) 1999-07-15
EP0536282A4 (en) 1993-05-05
JP2007063296A (ja) 2007-03-15
ES2100952T3 (es) 1997-07-01
EP0536282B1 (en) 1997-04-16
HK1006412A1 (en) 1999-02-26
CA2084775A1 (en) 1991-12-28
AU8207691A (en) 1992-01-23
JP2002308776A (ja) 2002-10-23
DE69125714T2 (de) 1997-10-23
GR3024064T3 (en) 1997-10-31
ATE151635T1 (de) 1997-05-15
IE912233A1 (en) 1992-01-01

Similar Documents

Publication Publication Date Title
DK0536282T3 (da) Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker
DK1203770T3 (da) Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme
LV12316A (lv) 16-aizvietoti 4-azoandrostani ka 5-alfa-reduktazes izozima 1 inhibitori
DE69516866D1 (de) Stereochemische wortmanninderivate
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
DK0981341T3 (da) Anvendelse af betulinsyrederivater til behandling og forebyggelse af melanom
ATE399007T1 (de) Raf kinase hemmer
NO960059L (no) Fremgangsmåte for behandling av en underjordisk formasjon
EP0758894A4 (en) Use of alpha-1c specific compounds to treat benign prostatic hyperplasia
DE69417925D1 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
DK0463664T3 (da) Fremgangsmåde til behandling af en underjordisk formation
NO911999L (no) Anvendelse av substituerte beta-hydroksyetylaminer som potente hemmestoffer til exoenzymer i sopp.
NO910884L (no) Utstyr for fjernstyrt innsetting av sementeringsplugger iundervannsborete broenner.
NO940862D0 (no) Neurotensinfremgangsmåte for inhibering av vaskulær lekkasje
NO965497L (no) Fremgangsmåte for kontrollert fiksering av avleiringsinhibitor i en underjordisk formasjon
NO912782L (no) Fremgangsmaate for behandling av skrap av legeringer av sjeldne jordmetaller/overgangsmetaller.
DK0588873T3 (da) Behandling af levercancer
ES2040750T3 (es) Un procedimiento para la preparacion de un derivado de isoquinolinol.
FI946189L (fi) 5-alfa-reduktaasi-inhibiittoreina käyttökelpoiset 17-alkyyliketonisteroidit
JPS51150116A (en) Repair technique for an undergro und hollow body
NO984043L (no) Ensileringsmiddel
SE8402957D0 (sv) Formstag till gjutveggsformar
DK0864032T3 (da) Fremgangsmåde til behandling af en underjordisk formation
NZ314002A (en) A method of inhibiting inflammatory cytokine formation using polyprenyl derivatives
ES2179227T3 (es) Poliolefinas modificadas con un monomero polifuncional insaturado que contiene un grupo imida y un grupo ester.